Investec Bank plc has filed a Form 8.5 regulatory disclosure revealing significant trading activity in Advanced Medical Solutions Group plc (AMS.L) ordinary shares.
The disclosure, made under Rule 8.5 of the UK Takeover Code, identifies Investec as an exempt principal trader acting in a client-serving capacity with recognised intermediary status.
Investec holds a dual role in relation to the transaction, serving as both advisor and joint broker to Advanced Medical Solutions Group plc throughout this process.
The dealings were carried out on 15th July 2026, with the formal public disclosure lodged the following day on 16th July 2026.
Trading data included in the filing shows that Investec purchased 200,000 ordinary shares at a price of 279.25 pence per unit during the dealing period.
On the sell side, Investec disposed of 111,323 ordinary shares, with prices ranging between 279.25 and 279.50 pence per unit across those transactions.
No cash-settled derivative transactions were reported in the filing, and no stock-settled derivatives or options activity was disclosed for the same period.
The disclosure also confirms that no indemnity arrangements, option agreements, or understandings exist that could serve as an inducement to deal or refrain from dealing.
Investec further confirmed there are no agreements relating to voting rights on relevant securities or future acquisition and disposal of securities linked to any derivative instrument.
The contact named in the filing is Abhishek Gawde, reachable at the telephone number listed within the official regulatory submission document.
All public disclosures of this nature under Rule 8 of the Takeover Code are required to be submitted to a recognised Regulatory Information Service for transparency purposes.
The UK Takeover Panel’s Market Surveillance Unit remains available for consultation regarding dealing disclosure obligations under the Code.
